SARS-CoV-2 Overview

Our Best-in-Class
COVID-19 Solutions

Reliable Detection and Differentiation

  • COVID-19 Testing

    As a worldwide leader in infectious disease immunoassays, Bio-Rad has been providing COVID-19 testing solutions from the earliest days of the pandemic. Bio-Rad offers a wide range of COVID-19 products for the screening, confirmation, surveillance, and assessment of unique immunological responses to natural infections and vaccinations. In addition, Bio-Rad offers SARS-CoV-2 quality controls that can be used for any SARS-CoV-2 serology method.

    Some products have limited regional availability. Please contact your local sales office for any product availability questions.

    Contact a Specialist
  • Discover Bio-Rad COVID-19 assays and research solutions

    • BioPlex 2200 SARS-CoV-2 IgG panel
    • Platelia anti-SARS-CoV-2 S IgG Quant assay
    • Platelia SARS-CoV-2 Total Ab assay
    • RDT COVID-19 Ag test
    • ddPCR instruments and reagents
    • SARS-CoV-2 ddPCR kit (CE-IVD)
    • Real-Time PCR instruments and reagents
    • SARS-CoV-2 RT-PCR assay kit
    • SARS-CoV-2 standards
    Learn more
Platelia SARS-CoV-2 Total Ab Assay

Platelia SARS-CoV-2 Total Ab Assay

This assay detects total anti-nucleocapsid antibodies (IgM, IgA, and IgG) to SARS-CoV-2 with high sensitivity (92% sensitivity for patients tested ≤8 days after symptom onset and 100% for patients tested >8 days after symptom onset). This blood-based immunoassay, designed for in vitro diagnostic testing, is the first serology assay with U.S. Emergency Use Authorization to test for total antibodies in a single assay. The test has also met requirements for applying the CE-mark in Europe.

Learn more Order now

Legal Notice:

The Platelia SARS-CoV-2 Total Ab Assay has been authorized by the FDA under an EUA for use by authorized laboratories. The test has not been FDA cleared or approved. The test has been authorized only for the presence of total antibodies against SARS-CoV-2, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

The Platelia SARS-CoV-2 Total Ab Assay has also met requirements for applying the CE-Mark in Europe and other certifications throughout the world (Australia TGA, Brazil ANVISA, Health Canada, Singapore HSA, etc.).

PLATELIA is a trademark of Bio-Rad Europe, GmbH in certain jurisdictions.